WIPOSchützen Sie diese Marke vor Nachahmern!
Mit unserer Markenüberwachung werden Sie automatisch per E-Mail über Nachahmer und Trittbrettfahrer benachrichtigt.
Die Internationale Marke BICYCLE RADIONUCLIDE THERAPY wurde als Wortmarke am 25.02.2022 bei der Weltorganisation für geistiges Eigentum angemeldet.
| Markenform | Wortmarke |
| Aktenzeichen | 1662119 |
| Registernummer | UK00003698774 |
| Länder | 
|
| Basismarke |
Nr. UK00003698774,
07. Januar 2022
|
| Anmeldedatum | 25. Februar 2022 |
| Ablaufdatum | 25. Februar 2032 |
Markeninhaber
Blocks A & B Portway Building,
Granta Park
GB
Granta Park
GB
Markenvertreter
Lacon London,
84 Theobalds Road,
GB
Waren und Dienstleistungen
05
Pharmaceuticals; pharmaceutical preparations; pharmaceutical
products; pharmaceutical products and preparations for use
in relation to oncology; pharmaceutical products and
preparations for use in relation to ophthalmology;
pharmaceutical products and preparations for use in relation
to neurology; anti-infective pharmaceutical products and
preparations; pharmaceutical products and preparations for
the treatment and/or prevention of respiratory disease;
pharmaceutical products and preparations for the treatment
and/or prevention of cardiovascular disease; pharmaceutical
products and preparations for the treatment and/or
prevention of metabolic disease; pharmaceutical products and
preparations for the treatment and/or prevention of viral
infections; pharmaceutical products and preparations for use
in diagnostics and imaging; pharmaceutical products and
preparations for the treatment and/or prevention of renal
disease; pharmaceutical products and preparations for the
treatment and/or prevention of gastrointestinal disease;
pharmaceutical products and preparations for the treatment
and/or prevention of muscular skeletal disease
42
Scientific and technological services and research and
design relating thereto; industrial analysis and research
services; pharmaceutical research and development services;
medical research and development services; pharmaceutical
testing and clinical trials; clinical trials; research and
development in the field of oncology; research and
development in the field of ophthalmology; research and
development in the field of neurology; research and
development in the field of anti-infective pharmaceuticals;
research and development in the field of respiratory
disease; research and development in the field of
cardiovascular disease; research and development in the
field of metabolic disease; research and development in the
field of antiviral drugs; research and development in the
field of diagnostics and imaging; research and development
in the field of renal disease; research and development in
the field of gastrointestinal disease; research and
development in the field of muscular skeletal disease;
information consultancy and advisory services relating to
the aforesaid
44
Medical services; medical testing; healthcare services;
pharmaceutical services; medical consulting services;
advisory services relating to pharmaceuticals; consultancy
and information services relating to pharmaceuticals;
medical services in the field of oncology; medical services
in the field of ophthalmology; medical services in the field
of neurology; medical services in the field of
anti-infectives; medical services in connection with
respiratory disease; medical services in connection with
cardiovascular disease; medical services in connection with
metabolic disease; medical services in connection with the
treatment and/or prevention of viral infections; medical
services in connection with diagnostics and imaging; medical
services in connection with renal disease; medical services
in connection with gastrointestinal disease; medical
services in connection with muscular skeletal disease;
pharmaceutical services in the field of oncology;
pharmaceutical services in the field of ophthalmology;
pharmaceutical services in the field of neurology;
pharmaceutical services in the field of anti-infectives;
pharmaceutical services in connection with respiratory
disease; pharmaceutical services in connection with
cardiovascular disease; pharmaceutical services in
connection with metabolic disease; pharmaceutical services
in connection with the treatment and/or prevention of viral
infections; pharmaceutical services in connection with
diagnostics and imaging; pharmaceutical services in
connection with renal disease; pharmaceutical services in
connection with gastrointestinal disease; pharmaceutical
services in connection with muscular skeletal disease;
information, consultancy and advisory services relating to
the aforesaid
Die Bezeichnungen wurden automatisch übersetzt. Übersetzung anzeigen
Markenhistorie
| Datum | Belegnummer | Bereich | Eintrag |
|---|---|---|---|
| 23. Februar 2023 | 2023/8 Gaz | JP | Ablehnung |
| 28. Oktober 2022 | 2022/44 Gaz | US | Ablehnung |
| 06. Oktober 2022 | 2022/40 Gaz | EM | Ablehnung |
| 25. Februar 2022 | 2022/18 Gaz | GB | Eintragung |
ID: 141662119